Skip to main content
. 2001 May 15;21(10):3375–3382. doi: 10.1523/JNEUROSCI.21-10-03375.2001

Fig. 5.

Fig. 5.

NGF (1 ng/ml)-enhanced ACh release involves Ca2+. A, The intracellular Ca2+ chelator BAPTA-AM (25 μm) inhibits NGF-induced ACh release during a short-term exposure. Data are expressed as a percentage of release in the absence of BAPTA-AM and NGF (mean ± SEM). Significance was determined using a one-way ANOVA with Tukey's post-test (*p < 0.001 vs control;† p < 0.001 vs NGF/BAPTA-AM).B, NGF-induced ACh release is inhibited by the voltage-gated Ca2+ channel antagonist Cd2+ (200 μm). Data are expressed as a percentage of release in the absence of Cd2+ and NGF (mean ± SEM; n = 6). Significance was determined using a one-way ANOVA with Tukey's post-test (*p < 0.001 vs control;†p < 0.001 vs NGF/Cd2+).